Humanigen Inc

Humanigen Inc (HGEN)

$0.149

[object Object]

(+1.36%)

Market is closed - opens 7 PM, 05 Jun 2023

Performance

  • $0.15
    $0.15
    $0.15
    downward going graph

    2.93%

    Downside

    Day's Volatility :4.34%

    Upside

    1.45%

    downward going graph
  • $0.09
    $3.25
    $0.15
    downward going graph

    38.4%

    Downside

    52 Weeks Volatility :97.16%

    Upside

    95.38%

    downward going graph

Returns

PeriodHumanigen Inc
3 Months
-6.29%
6 Months
5.52%
1 Year
-93.63%
3 Years
-98.46%

Highlights

Market Capitalization
17.7M
Book Value
- $0.42
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.5
Wall Street Target Price
0.33
Profit Margin
0.0%
Operating Margin TTM
-3061.21%
Return On Assets TTM
-85.05%
Return On Equity TTM
-2165.43%
Revenue TTM
1.7M
Revenue Per Share TTM
0.02
Quarterly Revenue Growth YOY
-78.7%
Gross Profit TTM
-209.5M
EBITDA
-9.0M
Diluted Eps TTM
-0.5
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.15
EPS Estimate Next Year
-0.09
EPS Estimate Current Quarter
-0.06
EPS Estimate Next Quarter
-0.06

Analyst Recommendation

Sell
    0
    0%Buy
    42%Hold
    57%Sell
Based on 7 Wall street analysts offering stock ratings for Humanigen Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
3
4
5
Sell
4
4
4

Analyst Forecast

What analysts predicted

Upside of 121.48%

Current $0.15
Target $0.33

Technicals Summary

Sell

Neutral

Buy

Humanigen Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Humanigen Inc
Humanigen Inc
-0.6%
5.52%
-93.63%
-98.46%
-98.46%
Moderna, Inc.
Moderna, Inc.
0.28%
-25.82%
-4.84%
117.92%
601.67%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.87%
-2.05%
21.5%
22.45%
137.1%
Seagen, Inc.
Seagen, Inc.
-1.61%
61.18%
37.09%
26.01%
217.64%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.63%
5.09%
23.88%
20.49%
123.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Humanigen Inc
Humanigen Inc
NA
NA
NA
-0.15
-21.65
-0.85
0.0
-0.42
Moderna, Inc.
Moderna, Inc.
11.46
11.46
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.91
19.91
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.18
26.18
0.41
14.61
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Humanigen Inc
Humanigen Inc
Sell
$17.7M
-98.46%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$49.1B
601.67%
11.46
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$80.7B
137.1%
19.91
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.5B
217.64%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$83.3B
123.04%
26.18
35.4%

Institutional Holdings

  • BlackRock Inc

    0.79%
  • Bank of New York Mellon Corp

    0.74%
  • Vanguard Group Inc

    0.59%
  • Geode Capital Management, LLC

    0.41%
  • Telemetry Investments, L.L.C.

    0.39%
  • UBS Group AG

    0.17%

Corporate Announcements

  • Humanigen Inc Earnings

    Humanigen Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

Humanigen, Inc. is developing its portfolio of Humaneered® monoclonal antibodies to address cutting-edge CAR-T optimization and oncology treatments advancing safer, better, and more effective cancer therapies. Derived from the company's Humaneered® platform, lenzilumab and ifabotuzumab are monoclonal antibodies with first-in-class mechanisms. Lenzilumab, which targets GM-CSF, is in development as a potential biologic therapy to make CAR-T therapy safer and more effective, as well as a potential treatment for rare hematologic cancers such as CMML and JMML. Ifabotuzumab, which targets the Eph type-A receptor 3 (EphA3), is being explored as a potential treatment for glioblastoma multiforme (GBM) and other deadly cancers, both as naked antibody and as part of an antibody-drug conjugate, as well as a backbone for a novel CAR-T construct, and a bispecific antibody platform.

Organization
Humanigen Inc
Employees
6
CEO
Dr. Cameron Durrant M.D., MBA
Industry
Biotechnology

FAQs